Skip to content
lifestyle.eastmnweeklynews.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
SAB Biotherapeutics, Inc.
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
April 15, 2026
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
March 19, 2026
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
March 10, 2026
←
Previous Page
1
2